Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Unicycive Therapeutics, Inc. (UNCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7285+0.0015 (+0.21%)
At close: 04:00PM EST
0.8100 +0.08 (+11.19%)
After hours: 06:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7270
Open0.7299
Bid0.7188 x 900
Ask0.7300 x 1100
Day's Range0.7150 - 0.7300
52 Week Range0.5110 - 2.3500
Volume45,668
Avg. Volume26,938
Market Cap10.908M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.63
  • GlobeNewswire

    Unicycive to Participate in Upcoming Investor Conferences

    Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial DysfunctionLOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced senior management will participate in two upcoming conferences: Sequire Technology ConferenceFormat: Company PresentationDate: Wednesday, November 30, 2022Time: 11:3

  • Benzinga

    Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies

    Unicycive Therapeutics Inc (NASDAQ: UNCY) announced key findings of UNI-494 efficacy from a preclinical study in Geographic Atrophy (GA). UNI-494 is a mitochondrial potassium channel (mitochondrial KATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver, and ocular diseases. Mitochondrial dysfunction is implicated in Age-related Macular Degeneration (AMD) progression. GA is an advanced form of AMD. The company evaluated the effect of UNI-

  • GlobeNewswire

    Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

    Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved drugs to slow the progression of AMD LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical s

Advertisement
Advertisement